This initial Phase I study will evaluate the safety, tolerability, and pharmacokinetics (PK)
of single and multiple ascending doses of CORT118335, the effect of concomitant
administration with food on exposure to CORT118335, and its pharmacological effect in healthy
subjects.
This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.
Recruiting
Corcept Therapeutics
Phase 2
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and
efficacy of miricorilant in obese adult with schizophrenia treated with antipsychotic
medications.
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Terminated
Corcept Therapeutics
Phase 2
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and
efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis
(NASH).
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
Completed
Corcept Therapeutics
Phase 1
This study will investigate if there is any difference in the amount of weight gained by
participants taking olanzapine with CORT118335 compared with olanzapine with placebo (a dummy
test medicine which looks like CORT118335 but contains no active medicine). Safety and
tolerability of CORT118335 when taken with olanzapine will also be evaluated.
Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants
Completed
Corcept Therapeutics
Phase 1
This study will evaluate the absolute bioavailability of CORT118335 and determine the mass
balance recovery, absorption, metabolism and elimination, and metabolite profile and
identification of metabolite structures following a single oral dose of CORT118335 in healthy
male participants.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
